BIONET Therapeutics Corp.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
At BIONET Therapeutics Corp., our focus is on regenerative medicinal products, Advanced tech-enabled research and development, exosomes, and gene/cell therapy.
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90272474
Status
Active
Number of Employees
0
Total Paid-in
Capital
700,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2024)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
BIONET Therapeutics Corp. is a patient-focused, R&D-driven global biopharmaceutical company, established in 2022. Our mission is to rapidly develop, manufacture, and provide regenerative medicine preparations and advanced cellular therapies to meet the evolving health needs of people at different stages of life. We are committed to staying at the forefront of this rapidly evolving field by prioritizing innovation, research, and development. With our patient-centered approach, we are dedicated to improving the lives of our patients and providing them with the highest level of care possible.
The content above was translated by Ai
